Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01246375

Enrollment

Registered

2010-11-23

Start date

2010-12-31

Completion date

2011-12-31

Last updated

2010-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.

Interventions

DEVICEDual energy X-ray absorptiometry

Device which measures bone density

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

60 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. Man at the minimum age of 60 years. 2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease. 3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years: Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion criteria

1. Usage of systemic steroids more than once during the 12 months prior to the study. 2. Usage of systemic steroids during the month prior to the study. 3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.

Design outcomes

Primary

Measure	Time frame
Diagnosis of Osteoporosis	3 month

Countries

Israel

Contacts

Primary ContactEitan Segal, B.Sc

eitansegal2@gmail.com97236947507

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026